mycophenolate mofetil
FDA Approved, EMA Approved
Description
Mycophenolate mofetil is an immunosuppressive agent that inhibits inosine monophosphate dehydrogenase, blocking de novo purine synthesis in lymphocytes. It is used in primary glomerular diseases including lupus nephritis, IgA nephropathy, and membranous nephropathy to reduce proteinuria and preserve renal function. The drug selectively suppresses T and B lymphocyte proliferation.
Indications & Therapeutic Use
primary glomerular disease, lupus nephritis, IgA nephropathy, membranous nephropathy, transplant rejection prophylaxis
Linked Diseases:
Global Availability (11 countries)
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
mycophenolate mofetil
| Generic Name | mycophenolate mofetil |
| Brands | 1 brand available |
| Active Ingredient | mycophenolate mofetil |
| Drug Class | primary glomerular disease |
| Manufacturer | Genentech/Roche |
| Dosage Forms | oral capsule 250 mg, oral tablet 500 mg, IV infusion 500 mg/vial, oral suspension 200 mg/mL |
| Medical Code | L04AA06 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00301561 |
| Countries | 11 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations12 Validated Nodes